CLINICAL_TRIALS
withdrawal
· 2012-01-25
Clinical Trial Update: Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia [Phase 1]
Summary
A Phase 1B open-label dose-ranging study of the oral agent AFX-2 in adults with chronic lymphocytic leukemia has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Afexa Life Sciences Inc | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Status: WITHDRAWN